Healthcare

  The global hormonal contraceptives market size is expected to showcase considerable growth by reaching USD 24,330.1 million by 2027 while exhibiting a CAGR of 5.4% between 2020 and 2027. This information is published by Fortune Business Insights in its latest report, titled, “Hormonal Contraceptives Market, 2020-2027.” The report further mentions that the market stood at USD 17,620.9 million in 2019 and is likely to experience considerable growth during the forecast period. This is attributable to the increasing focus on catering to the unmet demand for these contraceptives across the globe. List of the Companies Profiled in the Global Market: ·          Allergan (Dublin, Ireland) ·          Merck & Co., Inc . (New Jersey, United States) ·          Janssen Pharmaceuticals, Inc. (Beerse, Belgium) ·          Teva Pharmaceutical Industries (Petah Tikva, Israel) ·          Pfizer, Inc. (New York, United States) ·          Mylan N.V. (Pennsylvania, United States) ·  

  The global pharmaceuticals market size is set to decline marginally in 2020, from the pre-coronavirus outbreak projection of USD 1,316.0 billion to USD 1,310.0 billion, exhibiting a CAGR of 4.0% for the current year. Fortune Business Insights™ has revised its analysis of this market and brought out a special report, titled “ Impact Of Covid-19 On The Pharmaceuticals Market” , to study the short- and long-term effects of the pandemic on the growth of this market. According to Johns Hopkins University in the US, the global tally of confirmed COVID-19 cases has risen to 2.7 million, with the death toll standing at around 190,000 as of April 24, 2020. With most countries facing a treatment-deficit for this infection, pharmaceutical companies have diverted all their investment energies towards developing quick and effective drugs to cure affected people. Request Sample Copy: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/impact-of-covid-19-on-pharmaceuticals-market-1

The global pharmacovigilance (PV) market size is projected to reach USD 12.25 billion by 2027, exhibiting a CAGR of 12.3% during the forecast period. Initiation of awareness campaigns to disperse information among patients regarding safe medication practices will stimulate market growth, finds Fortune Business Insights™ in its report, titled “ Pharmacovigilance (PV) Market Size, Share & Industry Analysis, By Type (Service and Software), By Deployment (In-house and Outsource), By End User (Hospitals, Pharmaceutical Companies, and Others), and Regional Forecast, 2020-2027 ”. Prior to its commercial release, a drug has to undergo multiple trial phases and in each phase, its efficacy and safety are rigorously tested. Enhanced access to information has made people more aware about the safety of medicines, especially those given over-the-counter (OTC). This awareness is further bolstered by the initiatives taken at the local, national, and international level. Request Sample PDF: htt

The global prefilled syringes market size is projected to reach USD 9.53 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. Rising incidence of cancer and other Non-Communicable Diseases (NCDs) is expected to be the primary factor fueling the prefilled syringe market growth. According to the World Health Organization (WHO), 9 million deaths are caused by cancer worldwide every year. In total, NCDs cause close to 41 million deaths, or 71% of the global deaths, annually, states the WHO. The National Cancer Institute estimates that in the US alone, 1,735,530 new cancer cases were reported in 2018; by 2030, this figure is anticipated to reach 23.6 million. Such widespread prevalence of cancer and other NCDs has generated the need for alternative solutions such as biological drugs. The administration of these drugs requires modern devices such as prefilled syringes, which is foreseen to augment the prefilled syringes market potential in the forthcoming years. The repo

  The Global Diabetic Ulcer Treatment Market size is projected to reach USD 13.53 billion by the end of 2027. The increasing prevalence of diabetes will create several growth opportunities for the companies operating in the market. Diabetic ulcers are the most common symptom for patients with uncontrolled or unattended diabetes. These are severe conditions and can affect the bottom of your feet as well as the bones in this area. Almost all people suffering from diabetes are exposed at the risks of ulcers. The treatment of these ulcers can vary from patient to patient as well as the severity of the condition. The treatment can also vary depending on the cause of the ulcer. The severe symptoms associated with foot ulcers such as swelling, discomfort in walking, and redness and irritation, have led to a huge emphasis on the early detection and treatment of the disease. Additionally, mouth ulcers can also cause a lot of discomfort and pain and ultimately impede speech. The increasing inve

  The global point of care (POC) diagnostics market size is projected to reach USD 36.21 billion by 2028, exhibiting a CAGR of -1.9% during the forecast period. The prevalence of several chronic disorders and the incorporation of nanotechnology in diagnostic kits are likely to fuel market growth. Fortune Business Insights™ provides this information in its report titled " Point of care (POC) Diagnostics Market, 2021-2028. " List of Key Players Profiled in the POC Diagnostics Market Report ·          F . Hoffmann-La Roche Ltd (Basel, Switzerland) ·          Thermo Fisher Scientific Inc. (Massachusetts, U.S.) ·          Abbott Laboratories (Illinois, U.S.) ·          Quest Diagnostics Incorporated (New Jersey, U.S.) ·          BD (Franklin Lakes, U.S.) ·          bioMérieux SA (Marcy l'Etoile, France) ·          Cardinal Health, Inc. (Ohio, U.S.) ·          Mesa Biotech (California, U.S.) ·          Cepheid (California, U.S.) ·          Trinity Biotec